Verve Therapeutics (VERV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on the stock and has a $32.00 price target.
Whitney Ijem has given his Buy rating due to a combination of factors related to Verve Therapeutics’ recent developments and promising outlook. The company has received IND clearance from the FDA for its VERVE-102 to proceed with a Phase 1b clinical trial in the US, following positive interim data from international sites. This clearance, coupled with the absence of serious adverse events or significant lab abnormalities, suggests a strong safety profile for the treatment.
Furthermore, Verve’s ongoing partnership with Eli Lilly and the anticipated data update in the second quarter of 2025, which will include safety and biomarker data from multiple cohorts, reinforce the potential for successful outcomes. The company’s guidance towards efficacy similar to that of inclisiran, which has demonstrated significant reductions in PCSK9, adds to the optimism surrounding Verve’s future performance. These factors collectively underpin Whitney Ijem’s positive outlook and Buy rating for Verve Therapeutics.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
VERV’s price has also changed moderately for the past six months – from $4.950 to $5.780, which is a 16.77% increase.